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coronary heart disease (CHD) [1–3] but has been most widely studied
in patients with acute myocardial infarction (MI). A comprehensive
literature review of hospitalised post-MI patients estimates the
prevalence rate to be nearly 20% for major depression as measured
using clinical interviews [4]. Prevalences varied from 7.3% (Hospital
and Anxiety Depression Scale score ≥11) to 31.1% (Beck Depression
62 L. Poole et al. / Journal of Psychosomatic Research 71 (2011) 61–68Inventory (BDI) score ≥10) when using standardised questionnaires
measuring elevated depression symptomatology [4]. Similar esti-
mates have been reported more recently for both major and minor
depression, again in post-MI patients [5,6]. The association between
depression and cardiovascular morbidity following acute coronary
syndrome (ACS) was ﬁrst identiﬁed in the literature more than 15
years ago; Frasure-Smith et al. [7] showed that major depression in
patients recently admitted to hospital for MI was an independent risk
factor for mortality at 6 months. This association has been replicated
in several studies [8] and has been demonstrated in coronary artery
bypass graft (CABG) surgery patients as well [9]. The association with
recurrent cardiac disease is apparent not only for clinical depression,
but also for subclinical dysphoria and elevated symptoms of
depression within the normal range [10,11]. Moreover, depression
in CHD patients is associated with poorer quality of life after MI [12],
longer hospital stays and greater cardiac-related readmissions after
MI [13], greater disease progression (e.g., atherosclerosis in CABG
patients [14]) and increased use of urgent and unscheduled care
[13,15,16]. However, the mechanisms underlying the relationship
between depression and CHD have yet to be fully understood.
Depression is associated with traditional cardiac risk factors
including smoking, diabetes mellitus and hypertension [17] and of
particular salience may be physical inactivity [18]. Covariates have
been inconsistently controlled for across studies, making generalisa-
tion difﬁcult. However, it seems unlikely that these factors entirely
account for the relationship between depression and recurrent
cardiac events; for example, Frasure-Smith et al. [7] did not ﬁnd an
association between depression and cardiac risk factors (including
smoking, previous MI, Killip class, left ejection fraction, premature
ventricular contractions and thrombolysis), while other studies
controlled for a comprehensive range of risk factors statistically,
ﬁnding the relationship between depression and recurrent cardiac
events still remained [19]. Behavioural factors such as poor adherence
to lifestyle and medical advice may partly mediate the association
between depression and health outcomes in cardiac patients [20], but
other factors may also be signiﬁcant. Abnormal platelet function,
neuroendocrine dysfunction and disturbances in autonomic cardiac
control have all been proposed as mediating processes [21–23]. There
are several puzzling features to depression following ACS that
suggests a biological model may be useful to our understanding
[24–26]. The aim of this article is to outline the main features of
depression following ACS that result in future cardiac morbidity and
to put forward a model related to inﬂammation and sickness
behaviour that offers a framework for reconciling inconsistencies in
the current literature and for guiding future research. While
depression is also implicated in CHD onset [27], the focus of this
article is on depression following acute cardiac events. Much of this
work has been carried out with patients experiencing acute MI,
although responses are likely to be similar in other manifestations of
ACS. There is also growing evidence for the role of anxiety following
ACS in predicting adverse outcomes. A recent meta-analysis conclud-
ed that anxiety following MI is associated with a 36% increased risk of
adverse cardiac outcomes [28], although few studies have controlled
as comprehensively for covariates as in the studies of depression.
Characteristics of depression after an ACS
Timing of depression and later cardiovascular morbidity
The ﬁrst unusual feature of the relationship between depression
and CHD is that there appears to be a difference between those
patients who are depressed before the occurrence of an ACS and those
who develop depressive symptoms following the cardiac event.
Recent evidence indicates there is a stronger association with
mortality and recurrent cardiac events in patients with new-onset
depression (post-ACS depressed with no history of depression). Forexample, in a prospective cohort study of 588 patients admitted to
hospital with MI, Dickens et al. [29,30] observed 167 cases of
depression, of which 96 had depression before their MI and 71 who
developed depression during the 12 months following their MI.
Kaplan–Meier survival analysis showed that depression symptom-
atology from the week preceding MI did not confer risk of cardiac
mortality, but new-onset depression did (hazard ratio=2.33,
P=.038), even after controlling for a range of risk factors including
age, history of angina prior to MI, Killip class, beta-blocker use on
discharge, left ventricular fraction, use of antidepressant medication
at baseline and serious cardiac events during 12 months follow-up.
Similarly, de Jonge et al. [31] compared survival 1 year after acute MI
in nondepressed, new-onset depressed and recurrent depressed (i.e.,
post-ACS depressed but with a history of depression) patients and
showed an increased risk of recurrent cardiovascular events only in
the new-onset group, even after controlling for age, sex, education,
left ventricular ejection fraction and revascularisation. In a longer
follow-up study of 750 ACS patients (BDI scores: 515 patients ≤10;
235 patients ≥10), Grace et al. [32] showed that depression
symptomatology during hospitalisation after being admitted with
an ACS was predictive of 5-year mortality, but history of depression
was not. Parker et al. [33] conducted psychiatric interviews on 489
patients admitted to hospital with MI to diagnose patients with a pre-
ACS history of depression (observed in 187 participants) and new-
onset depression (observed in 57 participants at time of hospital
admission and 48 participants at 1 month follow-up). After control-
ling for covariates including age, sex, left ventricular ejection fraction,
diabetes, stroke, smoking and antidepressant use, results showed that
cardiovascular outcome was not associated with pre-ACS depression
nor with depression at the time of hospital admission; instead, the key
risk factor for cardiac relatedmortality was depression that developed
in the month following hospital admission. The small number of
depression cases limited the power of this study. The study with the
largest number of depression cases (550 recurrent and 370 new-onset
cases) by Carney et al. [34] showed that although both new-onset and
recurrent episodes of major depression predicted poor survival after
acute MI, new-onset major depression episodes were more strongly
predictive than recurrent episodes. An early study by Lesperance et al.
[35] found that recurrent depression with a new onset following
hospitalisation increased the risk of mortality at 18 months follow-up.
By contrast, recent ﬁndings from the Setraline Antidepressant Heart
Attack Randomised Trial (SADHART) found that although major
depression following admission predicted mortality over the next 7
years, timing of depression onset and a history of major depression
did not [36].
One explanation for this pattern proposed by Spijkerman et al. [37]
and later Goodman et al. [38] is that new-onset depression is
associated with more severe coronary artery disease than is recurrent
depression; however, the studies reported above [30,31,33] all
controlled for cardiac risk factors. It has been suggested that new-
onset depression has different risk factors to recurrent depression
[39], further indicating that it may be a distinct phenomenon. In
particular, negative perceptions regarding one's heart condition in the
days following an MI [40] or cardiac surgery [41] are associated with
increased risk of developing depression. In conclusion, it seems new-
onset cases of depression carry at least as much, if not more, risk as
chronic, recurrent depression.
Depression symptomatology
The second intriguing feature of the depression–CHD relationship
concerns the symptom proﬁle of patients with post-ACS depression
who are at risk for future cardiac events. Some types of symptoms
appear to be more “cardiotoxic” than others, with somatic symptoms
being particularly damaging. Analyses performed on two large data
sets comprising more than 2000 patients compared three dimensions
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cardiovascular risk markers, mortality and readmissions over an
average of 2.5 years after ACS [42]. Cox regression analyses found
somatic/affective symptoms (e.g., pessimism, fatigue) to predict
cardiovascular events and mortality, even after controlling cardiac
risk factors (left ventricular ejection fraction, Killip class and previous
MI), while cognitive/affective (e.g., social withdrawal, work difﬁculty)
and appetitive symptoms (e.g., loss of appetite, weight loss) did not
[42]. Somatic/affective rather than cognitive/affective symptomswere
also associated with an increased risk of cardiovascular related
mortality and MI severity in a prospective study following 473
patients for an average 2.8 years [43]. Other studies have focused on
speciﬁc somatic symptoms such as fatigue [44], with evidence that
symptoms of fatigue/sadness are associated with increased risk of
major cardiac events in patients up to 67 weeks post-ACS [45]. A more
recent study of women with suspected myocardial ischemia demon-
strated that both somatic/affective and appetitive (but not cognitive/
affective) symptoms on the BDI predicted cardiovascular mortality
and major events over a median of 5.8 years independently of
coronary artery disease severity scores at baseline and self-reported
history of cardiovascular-related events and conditions [46].
It should be noted not all evidence supports this association. For
example, an early study by Lesperance et al. [35] found that by
removing appetite and sleep disturbance symptoms from analyses,
depression was better able to predict mortality at 6 months. However,
a key limitation of this study is its small sample size, with only 42
depressed patients being followed-up at 6 months. Barefoot et al. [47]
administered the Zung Self Rating Depression Scale to patients with
stable coronary artery disease, with an average follow-up period of
15.4 years. They found that in a multivariate analysis of 867 patients,
only higher negative affect and hopelessness were able to predict
mortality and not somatic symptoms. However, this study did not
involve MI patients; thus, it does not readily generalise to this
population. Another study of stable CHD patients found that while
somatic depression symptoms were more predictive of cardiac events
than cognitive symptoms, they were also twice as likely to be
reported, suggesting that power for detecting associations with
cognitive symptoms may be an issue [48]. Davidson et al. [49] and
also Leroy et al. [50] have found anhedonia (markedly decreased
pleasure in activities) to be a key cardiotoxic symptom.
It is also interesting that somatic symptoms of depression overlap
with the concept of vital exhaustion, which is commonly deﬁned as
symptoms of excessive tiredness, increased irritability and a sense of
demoralisation [51]. Interestingly, vital exhaustion has been shown to
be predictive of cardiac prognosis in MI and heart failure patients [52].
Although depression and vital exhaustion are generally understood to
be separate constructs [53], more research is needed to delineate their
independent effects on the prognosis of ACS patients. Cultural
differences and variations in the depression assessment tool used
are also likely to impact the ﬁndings from these studies.
Limited responsiveness to treatment
A third feature is that depression following ACS responds relatively
poorly to standard treatment. The Enhancing Recovery in Coronary
Heart Disease (ENRICHD) randomised controlled trial compared
cognitive–behavioural treatment to usual case for depressed MI
patients [54] but showed only a modest and poorly sustained
difference in depression following treatment between the two groups.
Although statistically signiﬁcant, the improvement observed was only
between 1.5 and 2.8 points depending on the scale used, which is of
questionable clinical signiﬁcance. Another randomised controlled
trial, Canadian Cardiac Randomised Evaluation of Antidepressant and
Psychotherapy Efﬁcacy trial (CREATE) [55], used a two-factor factorial
design to compare interpersonal psychotherapy vs. clinical manage-
ment and citalopram vs. placebo pill. Citalopram had only a modesteffect on depression scores, and there was no evidence that
psychotherapy had a greater effect on depression than clinical
management. Subgroup analyses of the CREATE study showed a
better effect of citalopram on recurrent rather than ﬁrst depression, a
pattern that was not due to differences in cardiac disease severity or
the presence of vascular depression [56]. A multicentre trial in the
Netherlands (MIND-IT) compared ﬂexible pharmacotherapy (primar-
ily mirtazapine) with usual care in 331 depressed cardiac patients
[57]. There was no signiﬁcant difference between groups over 18
months either on depression case status or BDI score. A double-blind
placebo-controlled study of 369 ACS patients, SADHART [58], reported
greater improvements with sertraline (a selective serotonin-reuptake
inhibitor (SSRI)) on only one of two primarymeasures, with the effect
of treatment being greatest in those patients with severe and
recurrent depression. Similar to ENRICHD, however, the overall
difference between the groups was approximately 1 point on the
Hamilton Depression Rating Scale or 2.2 points in the subgroup of
patients with recurrent depression. Of importance here, a later
analysis indicated that episodes of major depression that began
after the ACS were less likely to respond to treatment than depression
that began before hospitalisation [59]. In a systematic review, Thombs
et al. [60] demonstrated only modest beneﬁts to antidepressant
treatment in cardiac patients, with effect sizes ranging from .20 to .38.
High rates of placebo response as opposed to low treatment responses
may, in large part, explain these results.
These clinical trials have also analysed the effect of treatment on
survival. The ENRICHD study failed to ﬁnd a difference between the
groups on event-free survival at 29 months follow-up [54], although
more recent analyses have suggested a beneﬁt of group therapy plus
individual therapy on mortality as compared with usual care [61].
Likewise, the MIND-IT trial failed to ﬁnd an effect of treatment on
cardiac events at 18 months follow-up [57]. In SADHART [58], a trend
towards fewer cardiac events was observed in the setraline group, but
this needs to be interpreted with caution because of the relatively
short follow-up period of only 6 months. A more recent publication
from this trial [36] showed that the severity of depression at baseline
and poor treatment responsivity were predictive of mortality at 7
years follow-up, which is in line with evidence that treatment-
resistant depression is linked to cardiac mortality [62,63].
The randomised trials described here have generally shown
limited depression treatment efﬁcacy in ACS patients. However, this
should be interpreted in light of evidence from noncardiac popula-
tions. Turner et al. [64] conducted a literature search of both published
and unpublished data on antidepressant efﬁcacy in psychiatric
populations, ﬁnding effect sizes that are comparable to the ENRICHD
and SADHART results. This suggests both noncardiac and cardiac
patients alike often respond poorly to standard treatment. One of the
difﬁculties in determining whether cardiac patients respond less well
to treatment is that many cases of depression resolve in the weeks
following the event, making a treatment effect hard to demonstrate.
The literature is suggestive of a reduced response to pharmacological
and cognitive behavioural treatment following ACS, but further
systematic studies are required fully to resolve this issue.
Summary
It can be argued that the form of depression in ACS that is
particularly cardiotoxic is a distinct disorder from psychiatric
depression. It is comprised of three elements, namely, new onset,
somatic symptoms and limited responsiveness to treatment. The
model we have described presents one way in which we can interpret
the differences in presentation of depression in ACS patients
compared with their psychiatric counterparts. An alternative expla-
nation is that the depression/future cardiac morbidity link is an
epiphenomenon and that the apparent association with recurrent
cardiac events is due to underlying coronary artery disease severity.
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coronary stenosis and by features of the ACS such as impaired left
ventricular function. A number of composite measures of risk have
been developed such as the Global Registry of Acute Events (GRACE)
index, which uses nine variables to predict survival, namely older age,
history of MI, history of heart failure, increased pulse rate at
presentation, lower systolic blood pressure at presentation, elevated
initial serum creatinine level, elevated initial serum cardiac biomarker
levels, ST-segment depression on presenting electrocardiogram and
not having a percutaneous coronary intervention performed in
hospital [65]. The predictive value of the index for short- and
longer-term morbidity has been conﬁrmed in independent studies
[66,67]. Other risk measures include the Simple Risk Index, the
EMMACE index and the PURSUIT index [68]. However, Lett et al. [69]
found no relationship between depression and disease severity in a
sample of over 1000 outpatients with stable CHD. Amore recent study
of 457 patients with ACS showed that that even after adjusting for
GRACE scores, the relationship between depression and cardiac
morbidity remained signiﬁcant [70]. Nevertheless, other biological
processes might be involved. For example, one possibility is that of the
so-called vascular depression hypothesis [71], which posits that
cerebrovascular disease can cause or perpetuate depression in elderly
individuals. While there is some evidence in support of this view in
ACS patients [72], recent analyses have not identiﬁed greater risk of
vascular depression in new-onset patients [56]. For example, a 6-year
prospective study of 3564 older adults found no association between
measures of atherosclerosis and new-onset depression [73]. An
alternative process that has received little attention to date is the
very large inﬂammatory response that occurs during acute cardiac
events.
An acute inﬂammation model of depression after major cardiac
events (ACS or CABG)
Inﬂammation and depression
Depression is associated with an innate inﬂammatory response
[74], and a meta-analysis by Howren et al. [75] has shown depressive
symptoms to be positively associated with C-reactive protein (CRP),
interleukin (IL) 1 and IL-6 in both clinical and community samples.
Epidemiological evidence for the directionality of the depression–
inﬂammation relationship is mixed, with some studies suggesting
that depression precedes inﬂammation [76], while others showing
that inﬂammation precedes depression [77].
The relationship has also been studied experimentally or quasi-
experimentally, testing the depressive responses to acute inﬂamma-
tory stimuli.
Vaccination studies
Inﬂammatory responses can be stimulated by administration of
endotoxin or by inoculation with attenuated vaccines. Reichenberg et
al. [78] used a cross-over design to test the effects of Salmonella
abortus equi endotoxin or saline on sickness symptoms and mood.
Blood was collected at baseline and at hourly intervals for up to 10
h postinjection. Results showed that healthy participants showed a
transient signiﬁcant increase in their levels of depressive and anxiety
symptoms in response to the endotoxin together with increases in IL-
6, IL-1 receptor antagonist (IL-1Ra) and tumour necrosis factor (TNF)
α. No differences in sickness were reported after the endotoxin as
compared with placebo. These results were conﬁrmed in a similar
study using S. typhi vaccine or placebo, reporting negative changes in
mood following injection with vaccine that were signiﬁcantly
correlated with increases in IL-6 production [79]. Notably, no
signiﬁcant symptoms of nausea were reported, so it cannot be argued
that negative moods arose because the participants were feeling ill.
Brain imaging studies indicate that the cytokine-induced moodresponse to typhoid vaccination is correlated with activity within
the subgenual anterior cingulate gyrus (sACC) and with reduced
connectivity between the sACC and amygdala, medial prefrontal
cortex, nucleus accumbens and superior temporal sulcus [80].
Interestingly, the inﬂammation induced by typhoid vaccination
impairs endothelial-dependent vascular dilatation, implicating tran-
sient endothelial dysfunction [81]. This may be the mechanism
underlying the transient increased risk of ACS in patients following
acute infections such as inﬂuenza [82]. In summary, vaccination
studies have shown that experimentally induced inﬂammation is
capable of triggering negative mood responses.
Immunotherapy-induced depression
A second set of literature that is relevant concerns clinical studies
investigating the effects of treatment with cytokine-based therapy on
mood. These studieswere stimulated by the observation of depression
in some patients with cancer treated with immunotherapy [83].
Capuron et al. [84] systematically investigated the association
between different immunotherapies (IL-2, IL-2 plus interferon (IFN)
α, subcutaneous IFN-α or intravenous IFN-α) and the development of
depressive symptoms in 33 patients with cancer. Patients treatedwith
IL-2 or IL-2 plus IFN-α showed concomitant increases in depression
symptoms and increased levels of the anti-inﬂammatory cytokine IL-
10 during treatment. Patients who are susceptible to inﬂammation-
induced depression are more likely to show higher depression
symptom scores prior to treatment [85] and a heightened pituitary–
adrenal response following the ﬁrst IFN-α injection [86]. Another
study showed that around one third of patients who were free of
depression before therapy developed major depression during
treatment with IFN-α [87]. Interestingly, Musselman et al. [88]
studied the effects of treatment with an antidepressant on depression
induced by IFN-α treatment in a randomised placebo-controlled trial
of 40 malignant melanoma patients. The intervention (paroxetine or
placebo) began 2 weeks before initiation of IFN-α therapy and
continued for 12 weeks. Results showed that there was a fourfold
reduction in risk of developing major depression by pretreatment
with paroxetine (an SSRI). To summarise, cytokine-based immu-
notherapy induces depressive symptomatology, and these effects can
be attenuated by pretreatment with antidepressant medication.
Animal work
Animal studies have also investigated the mechanisms linking
inﬂammatory responses with depression-like syndromes. A compre-
hensive review is provided by Dantzer et al. [89], who present two
lines of argument in support of the role of inﬂammation in the
development of depression.
First, inﬂammatory stimuli induce depression-like symptoms.
Frenois et al. [90] conducted an experiment using two measures
considered to be indicative of depressive state in animal models:
immobility and decreased preference for sweet solutions. They
showed that mice treated with a proinﬂammatory cytokine stimulant
(lipopolysaccharide) displayed increased immobility 24 h after two
stress tasks aimed to elicit a depressive response (tail suspension and
forced swim), even though motor activity had returned to normal. In
addition, preference for sweetened water was also reduced even after
food intake and drinking had returned to baseline levels. These effects
are more prominent in genetically vulnerable species. For example,
fawn-hooded rats, which exhibit many of the symptoms thought to
align with depression, are more sensitive to IL-1β-induced immobility
in the forced-swim test compared with controls [91].
Second, pharmacological corroboration for the role of inﬂamma-
tion has been provided by studies showing that depression-like
symptoms induced by exogenously administered inﬂammatory
stimuli can be attenuated with antidepressant drugs. For example,
pretreatment with the antidepressant drugs imipramine or ﬂuoxetine
blocked the reduced intake of sweetened solution and reduced social
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study, pretreatment with ﬂuoxetine abolished the impaired perfor-
mance of IL-1β-treated rats in a task designed to test reactivity to
reward (anhedonia) [94].
These ﬁndings indicate that animal models corroborate the human
literature with evidence that depression-like symptoms can be
experimentally induced by inﬂammatory stimuli and are likewise
responsive to pretreatment with antidepressant drugs.
Depression and low-grade inﬂammation in CHD patients
Depression has also been linked to inﬂammation in persons with
CHD, although the literature is somewhat inconsistent. Some evidence
shows depressed cardiac patients to have heightened inﬂammation;
for example, Bankier et al. [95] studied 72 CHD outpatients of whom
30 were classiﬁed as having major depressive disorder. Stepwise
multiple regression analyses revealed a signiﬁcant positive relation-
ship between depression and levels of CRP. Mixed ﬁndings were
found in a much larger study by Lesperance et al. [96] who assessed
481 outpatients 2months after hospitalisation for ACSwith diagnostic
psychiatric interviews. Depressed participants had higher levels of
soluble intracellular adhesion molecule 1, but there was no associa-
tion with IL-6. Frasure-Smith et al. [97,98] found patients with
elevated depression symptoms to have higher levels of CRP, but not
IL-6, as compared with nondepressed cardiac patients.
However, other studies have not supported this observation.
Schins et al. [99] conducted a case-controlled study of depressed
(n=57) and nondepressed (n=46) MI patients and found no
differences between the groups in levels of IL-6, TNF-α or CRP.
Frasure-Smith et al. [97] followed-up 741 patients for 2 years after
ACS for major adverse cardiac events and showed that elevated CRP
and BDI score 2 months after the cardiac event were both associated
with increased risk to a similar extent. In other studies, Empana et al.
[100] and, more recently, Davidson et al. [101] did not ﬁnd that
inﬂammation mediated the association between depression and
cardiac outcome.
One difﬁculty in the interpretation of this literature is the impact
of medications such as statins. In addition to their effects on cho-
lesterol synthesis, statins have marked immunomodulatory and anti-
inﬂammatory properties and modulate vascular endothelial function
[102]. Other cardiovascular medications are also anti-inﬂammatory
and have not been consistently taken into account. The relevance of
this literature is also called into question by the controversy
concerning the relevance of inﬂammation to prognosis in patients
with stable coronary artery disease. Contrary to guidelines issued by
the AmericanHeart Association, some authors [103,104] have recently
demonstrated that the literature relating elevated CRP with poor
prognosis is seriously ﬂawed, with poor control for confounders, poor
methodology and publication bias. The signiﬁcance of any associations
between inﬂammatory markers and future CHD risk in patients with
established disease is therefore uncertain.
Inﬂammation during ACS
An ACS is associated with a massive acute inﬂammatory response
[105,106]. The magnitude of the acute inﬂammatory response during
ACS is predictive of poor cardiac outcome. For example, Biasucci et al.
[107] showed in unstable angina patients that increases in IL-1Ra and
IL-6 measured 48 h after hospital admission were associated with
greater risk of in-hospital cardiac events, while elevated CRP predicts
14-day mortality in unstable angina and non-Q-wave MI indepen-
dently of troponin responses [108]. Further studies have conﬁrmed
this positive association in non-ST-segment elevation ACS patients
[109] and acute MI patients [106,109–113]. A recent meta-analysis of
20 cohort and randomised controlled trials showed that CRP levels
N10 mg/L measured within 72 h of ACS onset were associated with arelative risk of 2.18 (95% conﬁdence interval 1.77–2.68) for recurrent
cardiovascular events or death compared with values ≤3 mg/L [114].
Most of these studies controlled for age, sex, cardiac enzyme levels,
ejection fraction, heart failure and other markers of risk, suggesting
that the impact of acute inﬂammation is independent of multiple risk
indicators. The association between these large acute inﬂammatory
responses and subsequent depression has not been tested.
Coronary artery bypass graft surgery is also associated with an
acute inﬂammatory response. The contact with the surfaces of the
extracorporeal circuit inherent in cardiopulmonary bypass surgery
(on-pump) triggers a systemic inﬂammatory response that, in severe
cases, can lead to systemic inﬂammatory response syndrome; this is a
serious disorder capable of causing major organ dysfunction and
death [115]. Clinical management of the perioperative inﬂammatory
response is therefore critical to patient outcomes. An observational
study of 29 cardiopulmonary bypass patients by Holmes et al. [116]
used amedian split to compare outcomes between those patients who
showed a heightened inﬂammatory response to those who did not.
Findings showed that hyperresponders in IL-8, IL-6 and CR3 (an
anaphylatoxin) had increased risk of adverse clinical outcomes.
However, the small sample size limits the generalisability of these
ﬁndings. Other work has shown an acute inﬂammatory response not
only in on-pump but also off-pump surgery [117]. The extent of the
inﬂammatory response is thought largely to reﬂect the amount of
trauma derived from the surgical procedure itself and is associated
with a host of clinical outcomes, both cardiac and noncardiac in scope
[117,118]. However, there is a lack of studies in which perioperative
variables have been adjusted for, limiting the conclusions to be drawn
from these ﬁndings.
In summary, both ACS and CABG surgery are associated with an
acute inﬂammatory response. In ACS patients, this inﬂammation is
linked to prognosis; although the literature points towards this being
true in CABG populations as well, more high quality research is
needed.
Inﬂammation and depressive symptoms in patients with advanced CHD
(in ACS patients and following CABG)
Depression and poor outcomes in patients who experience ACS or
CABG appear to share a common inﬂammatory pathology. One way of
understanding the association among depression, acute coronary
events and inﬂammation is to draw on the literature on sickness
behaviour. Sickness behaviour refers to a cluster of symptoms
affecting both behavioural and affective state, triggered by the release
of proinﬂammatory cytokines commonly observed in response to a
systemic infection. In animals, sickness behaviour is reﬂected in social
withdrawal, decreased locomotion and exploratory activity and
reduced food and water intake. In humans, these are accompanied
bymalaise, increased negativemood, fatigue and listlessness. Parallels
can be drawn between sickness behaviour and the symptoms of
depression, including lassitude, fatigue and dysphoric mood, and this
similarity forms the basis for a sickness behaviour model of
depression in patients experiencing ACS or CABG. Sickness behaviour
is thought to be adaptive in organising bodily responses that ﬁght
infection, promoting cellular (T-helper 1) immunity, targeting
intracellular organisms through activation of macrophages, cytotoxic
T lymphocytes and natural killer cells [119]. However, in the case of
ACS and CABG, the extent of tissue trauma invokes a large
inﬂammatory response, capable of triggering a series of sickness
behaviours. In these vulnerable individuals, where the immune
response is exacerbated in duration and intensity, decompensation
(i.e., functional deterioration) occurs causing a shift in balance
between proinﬂammatory and anti-inﬂammatory cytokines towards
one of inﬂammation [89]. We hypothesise that under these conditions
sickness behaviours are no longer benign but instead can take on the
form of depression.
66 L. Poole et al. / Journal of Psychosomatic Research 71 (2011) 61–68In this review, we presented the case that depression in ACS and
CABG patients is distinct from that experienced in psychiatric
populations based on three features in which timing, symptom proﬁle
and treatment responsiveness are key. The model of inﬂammation
proposed would help to explain these differences by distinguishing
the pathogenesis of depression in ACS and CABG patients from that of
psychiatric patients. In ACS and CABG patients, the extent of the
inﬂammatory response is such that it may promote not only worse
cardiac outcomes but also depression. This depression is characterised
by more somatic symptoms that we have hypothesised are caused by
the activation of the sickness behaviour syndrome. In addition,
depression in acute cardiac patients shows a reduced treatment
response, possibly resulting from inﬂammation causing more phys-
ical, as opposed to affective, depression symptoms. Both these factors,
in turn, can be linked to poorer outcomes for these patients, since
there is substantial evidence that depression with concomitant
physical symptoms is associated with a longer depressive episode,
less response to treatment and less adherence to treatment [120].
The model of inﬂammation we propose is not exclusive, and other
pathways are certainly relevant. Indeed, there may be several forms of
depression within the ACS patient population, with only a subset
experiencing the inﬂammation-related syndrome described here. For
example, it is generally assumed that depression in the physically ill
results from illness burden (i.e., ongoing symptoms), role limitation
and associated loss events in people who are vulnerable, such as
through genetic vulnerability to depression or poor coping strategies.
The sickness behaviour model suggests there may be a direct
biological element to the development of depression, although there
is something still missing from this argument—inﬂammation elicits a
behavioural syndrome that resembles depression, yet it is not quite
depression. One explanation could be that these sickness behaviours
act as an additional burden among people who are already vulnerable.
Alternatively, it might be that there are neurocognitive changes
associated with inﬂammation that account for the behaviours and
possibly result in mood changes. Underlying this could be the effects
of inﬂammatory mediators on neurotransmitters such as serotonin
[121] or even minor damage to the central nervous system [122].
More research is needed to delineate these mechanisms in greater
detail.
Implications
This review is intended to stimulate different ways of viewing the
relationship between depression and adverse outcomes following ACS
and CABG, describing the ways in which depression manifests itself in
ACS patients and proposing an inﬂammatorymodel to account for this
presentation. This is unlikely to be the only mechanism, and other
pathways and processes are undoubtedly at work. Nevertheless, if an
inﬂammatory pathway is relevant, it would have several implications.
First, we would expect the magnitude of the acute inﬂammatory
response to predict the development of depression following acute
cardiac events or CABG and that ongoing inﬂammation might help
sustain depressive symptoms. Second, the size of acute inﬂammatory
responses might be associatedwith the biological mechanisms related
to future cardiac morbidity that are associated with depression,
including reduced heart rate variability, hypothalamic–pituitary–
adrenal axis dysregulation and impaired platelet function. Third, it
can be inferred that the association between depression after ACS or
CABG and adverse cardiac outcomes would be reduced if inﬂamma-
tion was included in the model. Finally, interventions that reduce
acute inﬂammation during cardiac events might reduce the magni-
tude of depressive responses. Current trials are evaluating techniques
for limiting acute inﬂammatory responses, for example, the MRC-ILA-
HEART study [123]. If these trials are successful, they would provide
the opportunity to test links between inﬂammation and the
development of depression in ACS patients.There are also important clinical implications of this hypothesis.
There has been a recent drive to effectively screen and manage
depression in ACS patients, an approach advocated by the American
Heart Association Prevention Committee [124]. The methods recom-
mended include routine screening of all cardiac patients for
depression using two short instruments—the Patient Health Ques-
tionnaire 2 and 9. This approach has been reviewed by Sowden et al.
[125], who found them to be feasible, well-accepted and not resource-
intensive. However, effective treatment for these patients continues
to pose a challenge. The lack of response to treatment of depression
following ACS is itself something of an anomaly, because inﬂamma-
tion-induced depression in melanoma patients [87] and depression-
like behaviour in animal models [92–94] are responsive to treatment.
While there is some evidence in favour of using an enhanced care
approach to alleviate depression symptoms, improve patient satis-
faction and reduce cardiac mortality in ACS patients [126], other novel
attempts to improve treatment efﬁcacy have not been so effective
[127]. There is some evidence that psychological therapies with a
behavioural component may be useful in reducing all-cause mortality
[128]. However, more work is still needed, and exploring the
mechanisms underpinning the relationship between depression and
ACS may provide an opportunity for developing more targeted and
selective therapeutic strategies. Other areas for future research
include elucidating the trajectory of inﬂammation over time and
understanding the processes by which acute inﬂammatory responses
during an ACS or CABG relate to subsequent elevations in inﬂamma-
torymarkers 2 to 8weeks after the event. In addition, more research is
needed to extend our knowledge of depression following an ACS to
the CABG surgery population; for example, does depression following
CABG have similar characteristics to those observed in ACS, with
somatic symptoms being particularly hazardous?
Conclusion
We have presented an argument for depression in ACS patients
and in patients following CABG being a qualitatively distinct form
from that observed in psychiatric populations. This is based on three
features: (1) depression developing after cardiac events is linked to
equally if not poorer outcomes as recurrent depression; (2) somatic
symptoms of depression following cardiac events are particularly
cardiotoxic; (3) depression following an ACS does not respond well to
antidepressant treatments. We have proposed that inﬂammation is a
common causal process responsible, in part, both for the development
of depressive symptoms and for adverse cardiac outcomes and have
drawn parallels with inﬂammation-induced sickness behaviour.
Future work is needed to test this pathway empirically and to
elucidate the complex interactions occurring between psychology and
physiology.
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